With $2M in Pre-Seed Funding, HeyRitual Launches to Take Couples Therapy Into the Digital Age
Ritual combines 1:1 guidance from experienced relationship experts with scientifically validated tools in a user-friendly platform
Logo HeyRitual…
Articles by Eric Jones
WHILL Power Chairs Announces Partnership With Stealth Products
Power chair experts team up to assist mobility-impaired consumers with a broader range of medical conditions
WHILL model F and C2 with Stealth Acce…
The AcCELLerate Forum to Focus on Creating a Sustainable Ecosystem of Cell and Gene Therapy
Virtual workshop on Nov. 17-18 bridges the gap between critical stakeholders to pinpoint today’s challenges and create forward-thinking solutions that enable the cell and gene therapy industry to create and deliver life-saving treatments equitably.
Be the Match
Be the Match
MINNEAPOLIS – October 24, 2022 – (Newswire.com)
The AcCELLerate Forum, a joint partnership between the American Society for Transplantation and Cellular Therapy (ASTCT™), the Center for International Blood and Marrow Transplant Research® (CIBMTR®), and the National Marrow Donor Program® (NMDP)/Be The Match®, brings key stakeholders together to identify ongoing needs and opportunities in cell and gene therapy for advocacy, measurement of value and impact and sustainability. The virtual workshop on Nov. 17-18, 2022, joins providers, payers, government agencies and industry members who will work together to define essential factors needed to create a sustainable cell and gene therapy ecosystem.
“NMDP/Be The Match is proud to be one of the sponsors of this important forum that has interests for all key stakeholders across the ecosystem,” said Jeffery Auletta, M.D., Senior Vice President, Patient Outcomes and Experience, of NMDP/Be The Match, Chief Scientific Director, CIBMTR. “Our established relationships with a global network of transplant centers and cell and gene therapy developers uniquely position NMDP/Be The Match to bring these experts together to identify the needs and opportunities in this field for advocacy, measurement, and sustainability.”
Dr. Auletta will join industry and transplant center partners and other professionals to address the question, “Are Center-Specific Outcomes Possible for CAR T-cell Immunotherapy?” The participants will focus on the perspectives of the payer, data acquisition and analysis, and center perspectives in defining outcomes for CAR T cells. They will also discuss healthcare inequity, specifically barriers to access and their impact on cell therapy outcomes. The speakers will incorporate the evolving cell therapy landscape from industry collaboration to clinical trials and real-world treatment in their presentations and in a moderator-led roundtable with attendee participation. Visit the event website to register and see the complete schedule and list of presenters.
In addition to NMDP/Be The Match, the event co-hosts include:
The American Society for Transplantation and Cellular Therapy (ASTCT) is an international professional membership association of more than 3,000 physicians, investigators, and other health care professionals from more than 45 countries. Our mission is dedicated to improving the application and success of blood and marrow transplantation and related cellular therapies. For more information about ASTCT, visit www.astct.org and follow us on Twitter, @ASTCT.
The CIBMTR, a research collaboration between the NMDP/Be The Match and the Medical College of Wisconsin, facilitates critical cellular therapy research through a clinical database of more than 600,000 patients from more than 350 centers worldwide, with a biospecimen repository of more than 195,000 samples.
Background:
The National Marrow Donor Program® (NMDP)/Be The Match® is the leading global partner working to save lives through cellular therapy. With 35 years of experience managing the most diverse registry of potential unrelated blood stem cell donors and cord blood units in the world, NMDP/Be The Match is a proven partner in providing cures to patients with life-threatening blood and marrow cancers and diseases. Through their global network, they connect centers and patients to their best cell therapy option—from blood stem cell transplant to a next-generation therapy—and collaborate with cell and gene therapy companies to support therapy development and delivery through Be The Match BioTherapies®. NMDP/Be The Match is a tireless advocate for the cell therapy community, working with hematologists/oncologists to remove barriers to consultation and treatment, and supporting patients through no-cost programs to eliminate non-medical obstacles to cell therapy. In addition, they are a global leader in research through the CIBMTR®—a collaboration with the Medical College of Wisconsin, investing in and managing research studies that improve patient outcomes and advance the future of care.
Contact Information:
Phyllis Grabot
[email protected]
Bonnie Quintanilla
[email protected]
Press Release Service
by
Newswire.com
Original Source:
The AcCELLerate Forum to Focus on Creating a Sustainable Ecosystem of Cell and Gene Therapy
Esophageal String Test®, a Less Invasive Way to Monitor Adults and Children With Eosinophilic Esophagitis (EoE), Launches in the US
Test offers EoE patients a simple, clinically proven method to control their disease. “…Beyond thrilled to use this at Phoenix Children’s Hospital…” – Dr. Schroeder, Medical Director, Eosinophilic Disease Clinic, Phoenix Children’s Hospital
AURORA, Colo. – October 24, 2022 – (Newswire.com)
Clinicians with the Gastrointestinal Eosinophilic Disease Program at the Digestive Health Institute, Children’s Hospital of Colorado, performed the Esophageal String Test® (EST) on a patient in early September. The test will be offered regularly at the hospital.
The EST was also performed on patients in the Eosinophilic Gastrointestinal Disease Clinic at Phoenix Children’s Hospital.
“I am now beyond thrilled to use this new esophageal surveillance technique at Phoenix Children’s and for my patients with eosinophilic gastrointestinal disorders. The EST is a game-changer for my patients who are looking for a less invasive and less expensive way to screen their disease activity,” said Dr. Shauna Schroeder, Medical Director for the Eosinophilic Gastrointestinal Disease Clinic at Phoenix Children’s Hospital. She further stated “Having trained in Denver, I had experience using the EST as a research tool in patients with eosinophilic esophagitis. I am now able to more granularly adjust medications and diets improving the care of my patients with eosinophilic esophagitis.”
The Esophageal String Test® utilizes a simple collection device, the EnteroTracker®, to collect upper gastrointestinal samples from adults and children. The samples are sent to an independent reference lab for analysis of disease activity. Several other clinics around the country are planning to offer the test soon.
About EnteroTrack
EnteroTrack, an early-stage company, develops simple-to-use, minimally invasive technologies to sample gastrointestinal (GI) mucosal content that can be assayed for various biomarkers of disease. The company’s platform technology, the EnteroTracker® is initially being used to support clinical monitoring of Eosinophilic Esophagitis in adults and children without need for sedation, advanced training, or complex procedures. Clinical studies evaluating the utility of the EnteroTracker® for additional applications including Esophageal Adenocarcinoma, Barrett’s Esophagus, GERD, GI microbiome, food allergy testing, and others are currently underway.
Contact Information:
Robin Shandas
CEO, Media and Investor Inquiries
[email protected]
Brookelynn Stillwell
General Inquiries
[email protected]
Press Release Service
by
Newswire.com
Original Source:
Esophageal String Test®, a Less Invasive Way to Monitor Adults and Children With Eosinophilic Esophagitis (EoE), Launches in the US
NOW Tonight with Joshua Johnson – May 20 | NBC News NOW
A Ukrainian governor says Russians have fired upon a school containing 200 people, a county in Iowa is turning to Latino …
CNN military analyst: Splitting Ukraine in 2 might look like this
Ukraine’s military intelligence head has warned that Putin could be looking at carving the country in two, similar to North and South Korea. CNN military analyst Cedric Leighton explains what a potential split of Ukraine would look like for Russ…
RBMA’s Radiology Patient Action Network Study Shows Nearly Half of Women Not Receiving Recommended Mammograms
RBMA Executive Director Bob Still decries Medicare cuts that would ‘damage the health of the American people’
RPAN Logo
RPAN Logo
WASHINGTON – October 20, 2022 – (Newswire.com)
A new study of current or eligible Medicare recipients conducted on behalf of the Radiology Patient Action Network shows that nearly half of women indicate that they have not received a mammogram in the last three years. Conducting and released during Breast Cancer Awareness Month, the study also found that 80 percent of Americans are concerned with proposed cuts to Medicare, and 90 percent of Americans view maintaining Medicare coverage as important.
“As policymakers continue to propose cuts to Medicare, it is clear any new cuts would worsen health inequities and damage the health of the American people,” said Bob Still, Executive Director of the RBMA. “At a time when patients are already having difficulty receiving the care they need — like mammography screenings proven to detect and prevent breast cancer — members of Congress should take note of these findings and protect Medicare.”
Dr. Kellie Schenk, a board-certified diagnostic radiologist with EPIC Imaging, PC, in Oregon and Imaging for a Cause participant, underscored the severity of the survey’s mammography findings. “Breast cancer is the most commonly diagnosed cancer among women and, if not caught and treated early, can be disfiguring and deadly. We recommend average-risk women receive mammography screenings every year beginning at age 40 and high-risk women talk to their doctor about screenings prior to 40 to increase the chances of early detection, which not only saves lives but makes treatment much easier and less disruptive for patients and their families. It is alarming that nearly half of Medicare-aged women haven’t received their annual mammogram given the benefits of screening in this age group, and we encourage them to get one scheduled as soon as possible. It is clear that further cuts to Medicare providers and vital screening services would only exacerbate this issue by limiting appointments and compromising quality of care.”
In addition to survey respondents’ concern for Medicare cuts and lack of mammography screenings, 1 in 4 current patients reported having difficulty scheduling doctors’ appointments due to delays or rescheduling. Almost half of all respondents said they would be less likely to support a member of Congress if they advocate for cuts.
The survey was conducted Sept. 25 through Sept. 27, 2022. The national survey sample consists of 1,632 Americans either enrolled in Medicare or Medicare-eligible. Margin of Error is +/-2.5% with a 95% level of confidence. The study was jointly sponsored by the Medical Imaging and Technology Alliance (MITA), Imaging for a Cause, and the Radiology Business Management Association (RBMA) and conducted by the Remington Research Group.
About Imaging for a Cause
Imaging for a Cause Foundation (ICF) is a 501(c)(3) nonprofit foundation that coordinates communication between imaging centers and Federally Qualified Community Health Centers. It has a decade-long history of fostering charitable care for thousands of patients, from Virginia to Minnesota to Washington State.
About MITA
The Medical Imaging & Technology Alliance (MITA), a division of NEMA, is the collective voice of medical imaging equipment manufacturers, innovators, and product developers. It represents companies whose sales comprise more than 90 percent of the global market for advanced medical imaging technology. For more information, visit www.medicalimaging.org.
About RBMA
The Radiology Business Management Association (RBMA) is an industry-leading organization comprised of more than 2,100 professionals who focus on the business of radiology. RBMA members support diagnostic imaging, interventional radiology and radiation oncology providers in the full spectrum of practice settings. RBMA connects members nationwide to valuable information, education, and practice-related resources and serves as an authoritative industry voice on behalf of shared member interests.
Contact Information:
Will Sweet
RBMA
[email protected]
Press Release Service
by
Newswire.com
Original Source:
RBMA’s Radiology Patient Action Network Study Shows Nearly Half of Women Not Receiving Recommended Mammograms
One of America’s Largest Employers of Psychiatrists, Talkiatry, Partners With Cedar to Enhance Patients’ Financial Experience
Talkiatry’s implementation of Cedar Pay brings a consumer-focused payment experience to a national patient base
NEW YORK – October 20, 2022 – (Newswire.com)
Talkiatry, a leading provider of high-quality, in-network psychiatric care and one of the largest employers of psychiatrists in the United States, announced today that it has partnered with Cedar, an enterprise healthcare engagement platform that improves the end-to-end consumer financial journey, to enhance the online billing experience for its rapidly expanding patient base.
Launched in 2020, Talkiatry is increasing the accessibility and affordability of high-quality psychiatric care. In network with over 60 major insurance plans, Talkiatry also conducts virtual visits that make it easy for patients to be seen. Talkiatry’s practice employs hundreds of psychiatrists from diverse backgrounds across a range of specialties—from child and adolescent to adult to geriatric—and uses proprietary technology to personalize care and improve outcomes in previously unachievable ways.
“In psychiatry, billing has long been a challenge for patients,” said Robert Krayn, Talkiatry’s co-founder and CEO. “It’s opaque and complex, and 45% of psychiatrists don’t even accept insurance. We’re changing that. We want our patients to focus on their health, not on trying to decipher confusing statements, and Cedar is an important part of how we use technology to improve the patient experience.”
Cedar Pay, Cedar’s post-visit patient engagement and payment platform, delivers a more streamlined patient financial journey and eases the consumer burden of paying for healthcare. Through Cedar Pay, Talkiatry will be able to empower their national patient base to better manage their healthcare bills through consumer-friendly statements, optimized outreach and flexible payment options.
“It is often difficult for Americans to access mental health treatment, due to factors like cost of care and lack of in-network providers,” said Florian Otto, Cedar’s co-founder and CEO. “At Cedar, our mission is simple: empower people to easily and affordably pursue the care they need, and we are looking forward to partnering with our first psychiatry provider, Talkiatry, as they enhance their digital strategy to meet patients where they are. And, with a simplified payments experience, their psychiatry providers will be able to focus on providing the best quality care.”
Cedar Pay is now live and available for Talkiatry’s patients.
About Talkiatry
Talkiatry is a national mental health practice that provides in-network psychiatry and therapy. They were co-founded by a patient and a triple-board-certified psychiatrist to solve the problems both groups face in accessing and providing the highest quality mental healthcare. 60% of adults in the U.S. with a diagnosable mental illness go untreated every year because care is inaccessible, while 45% of clinicians are out of network with insurers because reimbursement rates are low and paperwork is unduly burdensome. With innovative technology and a human-centered philosophy, Talkiatry provides patients with the care they need—and allows psychiatrists to focus on why they got into medicine. Learn more at www.talkiatry.com and follow us on Instagram, Facebook, and LinkedIn.
About Cedar
Cedar is committed to improving the healthcare billing experience for all. With an innovative platform that connects providers and payers, Cedar empowers healthcare consumers with a personalized journey—all powered by data science and interactive design. For Cedar clients, this leads to increased payments, more efficient operations and greater consumer loyalty. To learn more about why leading U.S. healthcare organizations trust Cedar to manage the end-to-end payments experience from pre-registration to post-visit billing, visit www.cedar.com and join us on LinkedIn, Twitter, Facebook and YouTube.
Contact Information:
Jenny Fiegoli
Cedar
[email protected]
Hirsch Leatherwood
Talkiatry
[email protected]
Press Release Service
by
Newswire.com
Original Source:
One of America’s Largest Employers of Psychiatrists, Talkiatry, Partners With Cedar to Enhance Patients’ Financial Experience
Inspire Medical Systems, Inc. Expands Therapy Access to Thousands of Federal Medical Facilities Through SDVOSB Partner, Lovell Government Services, Inc.
Inspire and Lovell are proudly partnered Inspire is now available on major government contract vehicles through Lovell, SDVOSB
PENSACOLA, Fla. – …
Scitech and the Plough Center Announce Manufacturing Agreement
The Contract Manufacturing Agreement Will Provide the Clinical Supply of ST-001, SciTech’s Lead Drug Candidate for Cancer
GROSSE POINTE FARMS, Mich. – October 20, 2022 – (Newswire.com)
SciTech Development is pleased to announce that it has signed a $600K manufacturing agreement with The Plough Center for Sterile Drug Delivery Systems. The Plough Center will deliver the clinical supply of SciTech’s lead cancer drug candidate, ST-001 nanoFenretinide. Delivery of the drug is expected in Q4 2022, which will be immediately followed by SciTech’s first human clinical trial using ST-001 for Lymphoma. (ClinicalTrials.gov Identifier: NCT04234048).
Earle Holsapple, President of SciTech Development, said, “SciTech chose The Plough Center for their expertise in drug delivery manufacturing in addition to their intimate knowledge of combining and processing nanoparticles. We are confident that SciTech has selected the best possible partner and that this relationship will continue as we move forward, not only with ST-001, along with other drugs in our pipeline. This is a major milestone for SciTech as we rapidly approach our human clinical trials.”
“We are excited to serve as the contract manufacturer for ST-001. We are extremely eager to work with SciTech in its mission to cure several cancer types,” said Dr. Harry Kochat, Director of Operations and Business Development of The Plough Center. “ST-001 nanoFenretinide combines the SciTech Delivery Platform (SDP) and the promising drug fenretinide as a broadly applicable cancer therapeutic. The Plough Center will utilize our comprehensive NanoSpace formulation platform to provide ST-001 for clinical trials. Our in-house NanoSpace platform can produce nanosuspensions, nanoemulsions, and liposomal encapsulation products.” The Plough Center specializes in developing and manufacturing complex, early-stage investigational drugs.
About SciTech Development
SciTech Development LLC is a clinical-stage pharmaceutical company that has developed a patented, nanoparticle drug delivery platform (SDP) that maximizes the bioavailability of water-insoluble therapeutics. SciTech’s lead drug candidate ST-001 nanoFenretinide combines SDP and the drug fenretinide as a broadly applicable anticancer drug. ST-001 has an FDA Investigational New Drug (IND) approval, is Orphan Drug designated, and is Phase 1 clinical trial ready. More information about SciTech can be found at www.SciTechSDP.com.
About The Plough Center
The mission of The Plough Center for Sterile Drug Delivery Solutions is to help patients by expediting efforts to bring innovative, life-saving medicines to market. The Plough Center is a US-FDA registered cGMP sterile drug manufacturing facility owned by the University of Tennessee Health Science Center in Memphis. Plough assists universities, scientific communities, and the pharmaceutical industry in the manufacture and delivery of therapeutic advances that will improve patient standard of care. More information about The Plough Center can be found at https://www.uthsc.edu/plough-center/.
Contact Information:
Harry Kochat, PhD.
Director of Operations & Business Development
[email protected]
David Schaffer
Director Investor Relations
[email protected]
Press Release Service
by
Newswire.com
Original Source:
Scitech and the Plough Center Announce Manufacturing Agreement